The Innovation Firm

When

September 27, 2018
12:00 - 2:00 PM

Where

MassBio, 8th Floor
300 Technology Square
Cambridge, MA 02139

Navigate Your Way to a Successful Commercialization of your Invention

Representatives from Jounce Therapeutics, Novo Nordisk, MIT, Sensera Inc., and Hamilton Brook Smith Reynolds discussed industry paradigms and the patent system requirements for commercializing and protecting innovations. Through a panel discussion and audience participation, they covered the following topics:

  • Strategies for approaching potential partners
  • Factors that drive decisions for licenses, joint ventures,
    acquisitions, and public offerings
  • Information to provide to potential partners
  • Timing considerations for partnering and patenting

Panelists:


Anna Barry, Ph.D.
Sr. Vice President, General Counsel & Secretary
Jounce Therapeutics


Aaron Schwartz
Director, Search & Evaluation, Global Drug Discovery
Novo Nordisk


Lauren Foster
Associate Director
Massachusetts Institute of Technology


Dr. Jack Salerno
Business Development Officer
Sensera, Inc.


Deirdre Sanders
Principal
Hamilton Brook Smith Reynolds


Mark Solomon
Principal
Hamilton Brook Smith Reynolds

Timing considerations for partnering and The event will include a networking lunch, panel presentation, and Q&A session with dess

Anna Barry, Ph.D.
Senior Vice President, General Counsel & Secretary
Jounce Therapeutics

Dr. Barry brings to Jounce more than 15 years of intellectual property, corporate and transactional legal experience in the biotechnology industry. Prior to joining Jounce Therapeutics, Dr. Barry was senior intellectual property counsel at Five Prime Therapeutics, where she managed all aspects of intellectual property related to the company’s therapeutic pipeline and platform technology.

 

Aaron Schwartz
Director, Search & Evaluation, Global Drug Discovery
Novo Nordisk

Aaron has been a Director in Novo Nordisk’s Search & Evaluation team in Global Drug Discovery since 2016. Aaron is responsible for the search and evaluation of new therapeutics and enabling technologies for protein, peptide, and antibody drugs. Prior to joining Novo Nordisk, Aaron worked in the MIT Technology Licensing Office for 13.5 years. 

 

Lauren Foster
Associate Director
Massachusetts Institute of Technology

Director of IP and Strategic Alliances at Koch Institute. Medicine, Cell Biology, Biotechnology, Diagnostics.

 

Dr. Jack Salerno
Business Development Officer
Sensera, Inc.

Over 25 years’ experience in corporate operations, product development and product commercialization with a career spanning R&D management to corporate CEO in high tech microsystems. Jack is also an EVP at Triton Systems having earlier held title of President at Agiltron and VP at Kopin Corporation, where he established one of the first compound semiconductor epitaxial wafer businesses.

 

Deirdre Sanders
Principal
Hamilton Brook Smith Reynolds

Deirdre has 20 years of experience in strategic biotechnology patent prosecution counseling and in intellectual property litigation and enforcement. Deirdre’s patent practice is focused in the field of biotechnology with a particular emphasis in the areas of biologics including antibody-based therapeutics, pharmaceuticals, medical devices, immuno-oncology and immunotherapy, bioinformatics, protein-based sensors, and drug discovery and development.

 

 

Mark Solomon
Principal
Hamilton Brook Smith Reynolds

Mark has dedicated his 19-year legal career to guiding engineering companies and university engineering centers through the development, management, protection, and enforcement of intellectual property rights. He provides high value IP services for clients who value IP by drafting and prosecuting patent applications from strategic business or licensing perspectives, as applicable.

 

 

Overview

When

September 27, 2018
12:00 - 2:00 PM

Where

MassBio, 8th Floor
300 Technology Square
Cambridge, MA 02139

Representatives from Jounce Therapeutics, Novo Nordisk, MIT, Sensera Inc., and Hamilton Brook Smith Reynolds discussed industry paradigms and the patent system requirements for commercializing and protecting innovations. Through a panel discussion and audience participation, they covered the following topics:

  • Strategies for approaching potential partners
  • Factors that drive decisions for licenses, joint ventures,
    acquisitions, and public offerings
  • Information to provide to potential partners
  • Timing considerations for partnering and patenting

Panelists:


Anna Barry, Ph.D.
Sr. Vice President, General Counsel & Secretary
Jounce Therapeutics


Aaron Schwartz
Director, Search & Evaluation, Global Drug Discovery
Novo Nordisk


Lauren Foster
Associate Director
Massachusetts Institute of Technology


Dr. Jack Salerno
Business Development Officer
Sensera, Inc.


Deirdre Sanders
Principal
Hamilton Brook Smith Reynolds


Mark Solomon
Principal
Hamilton Brook Smith Reynolds

Timing considerations for partnering and The event will include a networking lunch, panel presentation, and Q&A session with dess

Presenter Bios

Anna Barry, Ph.D.
Senior Vice President, General Counsel & Secretary
Jounce Therapeutics

Dr. Barry brings to Jounce more than 15 years of intellectual property, corporate and transactional legal experience in the biotechnology industry. Prior to joining Jounce Therapeutics, Dr. Barry was senior intellectual property counsel at Five Prime Therapeutics, where she managed all aspects of intellectual property related to the company’s therapeutic pipeline and platform technology.

 

Aaron Schwartz
Director, Search & Evaluation, Global Drug Discovery
Novo Nordisk

Aaron has been a Director in Novo Nordisk’s Search & Evaluation team in Global Drug Discovery since 2016. Aaron is responsible for the search and evaluation of new therapeutics and enabling technologies for protein, peptide, and antibody drugs. Prior to joining Novo Nordisk, Aaron worked in the MIT Technology Licensing Office for 13.5 years. 

 

Lauren Foster
Associate Director
Massachusetts Institute of Technology

Director of IP and Strategic Alliances at Koch Institute. Medicine, Cell Biology, Biotechnology, Diagnostics.

 

Dr. Jack Salerno
Business Development Officer
Sensera, Inc.

Over 25 years’ experience in corporate operations, product development and product commercialization with a career spanning R&D management to corporate CEO in high tech microsystems. Jack is also an EVP at Triton Systems having earlier held title of President at Agiltron and VP at Kopin Corporation, where he established one of the first compound semiconductor epitaxial wafer businesses.

 

Deirdre Sanders
Principal
Hamilton Brook Smith Reynolds

Deirdre has 20 years of experience in strategic biotechnology patent prosecution counseling and in intellectual property litigation and enforcement. Deirdre’s patent practice is focused in the field of biotechnology with a particular emphasis in the areas of biologics including antibody-based therapeutics, pharmaceuticals, medical devices, immuno-oncology and immunotherapy, bioinformatics, protein-based sensors, and drug discovery and development.

 

 

Mark Solomon
Principal
Hamilton Brook Smith Reynolds

Mark has dedicated his 19-year legal career to guiding engineering companies and university engineering centers through the development, management, protection, and enforcement of intellectual property rights. He provides high value IP services for clients who value IP by drafting and prosecuting patent applications from strategic business or licensing perspectives, as applicable.

 

 

Back to the Top